title: Secondary haemochromatosis in a haemodialysis patient.
abstract: A 39-year-old woman with end-stage renal disease, which was maintained on haemodialysis, developed secondary haemochromatosis after receiving blood transfusions and intravenous iron supplementation without sufficient serum ferritin concentration monitoring. The patient received intravenous deferoxamine three times a week, combined with high-dose recombinant human erythropoietin therapy and haemodialysis. After three months, improvements in biochemical indicators and iron overload were noted.
authors.affiliation: Division of Nephrology, West China Hospital, Sichuan University, Sichuan, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Cheng
authors.affiliation: Division of Nephrology, West China Hospital, Sichuan University, Sichuan, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Tang
authors.affiliation: Division of Nephrology, West China Hospital, Sichuan University, Sichuan, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Fu
authors.affiliation: Division of Nephrology, West China Hospital, Sichuan University, Sichuan, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
mesh_terms: D000328:Adult; D002614:Chelating Agents / Q000737:chemistry; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood*; D006432:Hemochromatosis / Q000150:complications*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D017422:Sequence Analysis, DNA; D014057:Tomography, X-Ray Computed; D014168:Transferrin / Q000737:chemistry; D065227:Transfusion Reaction; D016896:Treatment Outcome
chemical_list: D002614:Chelating Agents; C554270:EPO protein, human; D006454:Hemoglobins; D011994:Recombinant Proteins; D014168:Transferrin; D004921:Erythropoietin; D005293:Ferritins
keywords: ESRD; HFE gene; deferoxamine; haemodialysis; secondary haemochromatosis